Priority Review Sets Up Sanofi’s ‘Best In Disease’ Hemophilia Drug For 2023 Launch
Will Beat Gene Therapy To US Market
Executive Summary
Sanofi can now expect an FDA decision in early 2023 on efanesoctocog, setting it up for a battle with Roche’s Hemlibra and BioMarin’s gene therapy Roctavian, which was just approved in the EU.
You may also be interested in...
J&J-Bound Reed Reaches End Of The Road As Sanofi R&D Chief
The French drugmaker has begun an external and internal search to succeed John Reed who is heading for Johnson & Johnson after an up-and-down five years as Sanofi’s R&D chief.
Sanofi Reports Uninspiring Q4 Sales Amid Skepticism On Dupixent’s COPD Potential
The French firm’s Q4 sales missed consensus due to a slow-down in its vaccine franchise, while analyst concern regarding a pivotal readout for blockbuster product Dupixent in COPD increased.
J.P. Morgan Day Three: 2023 Is A Year Of Commercial Challenges
Daily notebook from the J.P. Morgan Healthcare Conference: Gene therapy Vertex enters pricing negotiations on gene therapy, Sanofi sees opportunity in hemophilia despite new gene therapy, and AbbVie raises guidance ahead of the introduction of Humira biosimilars. Plus ICER's Steven Pearson and former Biogen CEO George Scangos weigh in on Alzheimer's developments.